

## **Dynavax Announces Presentation of Clinical Data at ASH Annual Meeting**

BERKELEY, CA -- (Marketwired) -- 11/30/15 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that it will present clinical data at the 57<sup>th</sup> American Society of Hematology (ASH) Annual Meeting this weekend in Orlando, Florida. The details for the poster presentation are as follows:

**Date and Time:** Saturday, December 5, 2015, 5:30pm - 7:30pm EST

**Abstract Title:** Regulatory T Cells Are Depleted in Low-Grade Lymphoma By the Combination of Local Low-Dose Radiation Followed By Intratumoral CpG-ODN.

**Session Number:** 616

**Session Name:** Lymphoma: Therapy with Biologic Agents, excluding Pre-Clinical Models: Poster I

**Abstract Number:** 1539

**Location:** Hall A, Level 2 (Orange County Convention Center)

Please click [here](#) for the full abstract. The poster presentation with updated data will be made available on or after December 5, 2015.

### **About SD-101**

SD-101, the subject of ASH abstract 1539, is Dynavax's proprietary, second-generation, TLR 9 agonist CpG-C class oligodeoxynucleotide. SD-101 activates multiple anti-tumor activities of innate immune cells and activates plasmacytoid dendritic cells to stimulate T cells specific for antigens released from dying tumor cells. TLR9 agonists such as SD-101 enhance T and B cell responses and provide potent Type 1 interferon induction and maturation of plasmacytoid dendritic cells to antigen-presenting cells. SD-101 is being evaluated in several Phase 1/2 oncology studies to assess its preliminary safety and activity.

### **About Dynavax**

Dynavax, a clinical-stage biopharmaceutical company, discovers and develops novel vaccines and therapeutics in the areas of infectious and inflammatory diseases and oncology. Dynavax's lead product candidates are HEPLISAV-B™, a Phase 3 investigational adult hepatitis B vaccine and SD-101, an investigational cancer immunotherapeutic currently in several Phase 1/2 studies. For more information, visit [www.dynavax.com](http://www.dynavax.com).

### **Contact:**

Michael Ostrach  
Chief Financial Officer  
510-665-7257  
[Email Contact](#)

Source: Dynavax Technologies

News Provided by Acquire Media